肿瘤细胞治疗研究
英文原题：Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy.
尽管高达80%的霍奇金淋巴瘤（HL）患者通过一线治疗获得治愈，但复发/难治性HL仍是主要的临床障碍，对于不适合自体干细胞移植（ASCT）或治疗后复发的患者而言，该病具有致命性。
多达80%的霍奇金淋巴瘤（HL）患者可经一线治疗治愈，但复发/难治性HL仍是重要临床难题；对于不适合自体干细胞移植（ASCT）或移植后复发的患者，该病可致命。近年来，研究者探索了多种免疫治疗方法，旨在通过免疫系统对癌细胞产生反应来发挥潜在抗肿瘤作用。针对新型药物（包括brentuximab vedotin（BV）和PD-1抑制剂）的临床研究，已成功证实其对ASCT后复发疾病的疗效。此外，为降低复发风险和化疗相关毒性而开展的联合治疗研究也显示出令人鼓舞的结果，主要见于未经治疗、早期但预后不良或晚期经典型HL（cHL）患者。其他尚未获批的免疫疗法，如camidanlumab tesirine、CD30/CD16A双特异性抗体和CD30嵌合抗原受体（CAR）T细胞疗法，也具有前景，有望丰富患者可选的治疗手段。
Although up to 80 % of Hodgkin lymphoma (HL) patients are cured with first-line therapy, relapsed/refractory HL remains a major clinical obstacle and is fatal for patients who are not candidates for autologous stem cell transplantation (ASCT) or relapse after treatment. Several immune-based approaches have been investigated in recent years with the aim of exerting a possible antitumor effect through the immune system response to cancer cells. Clinical studies on novel agents, including brentuximab vedotin (BV) and PD-1 inhibitors, have successfully demonstrated their effectiveness in relapsed disease after ASCT. Additionally, studies examining combination strategies with the goal of reducing the risk of relapse and chemotherapy-related toxicity have showed encouraging results, mainly in untreated early unfavorable or advanced stage classical HL (cHL). Other non-approved immunotherapies such as camidanlumab tesirine, bispecific CD30/CD16A antibody, and CD30 chimeric antigen receptor (CAR) T-cell therapy are promising approaches that may reinforce the therapeutic arsenal available to patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
